Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Fast Forward, LLC and Provid Pharmaceuticals Announce Expansion of their Partnership for the Development of PV-267, Provid’s Unique MS Drug Candidate

November 17, 2010 By Bio-Medicine.Org

NEW YORK and NORTH BRUNSWICK, N.J., Nov. 17, 2010
/PRNewswire/ — Provid Pharmaceuticals, Inc, a drug
discovery company, and Fast Forward, LLC, the
National Multiple Sclerosis Society’s subsidiary devoted to
bridging the gap between research and drug development, today
announced an expansion of their partnership to support Provid’s
preclinical studies of their candidate MS drug, PV-267.  This
novel, highly selective small molecule is designed to block a
critical step in the autoimmune process of MS, which leads to the
destruction of the body’s protective myelin in the central nervous
system and to the ultimate accumulation of disability.  

The expanded partnership will enable Provid to enhance knowledge
of the immune mechanisms involved in the activity of PV-267, paving
the way for future development and clinical studies.  The
biological studies will be carried out by Dr. Thomas Forsthuber,
Provid’s collaborator and a leading immunologist at the University
of Texas San Antonio.  

“The partnership between Fast Forward and Provid was
begun in May 2009 and helped fund important research,” noted Dr.
Gary Olson, Provid’s President and CEO.  “In these studies,
PV-267 was shown to be active in an animal model of MS in
transgenic mice that carry the human gene for HLA-DR2, a
disease-associated molecule that is involved in the attack of the
immune system on myelin, the insulating protein on nerves that are
damaged in MS.”  Dr. Olson added, “DR2 is present in about 60%
of the MS population and PV-267 was designed to be a potent and
selective blocker of DR2.  This specificity suggests that
PV-267 could have a better safety profile compared with
immune-modifying therapies since it will not affect other, normal
immune responses.”  

The partnership with Provid is one of a series of partnerships
between Fast Forward and early stage biotechnology
companies. “The results of our

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech